On human lung parenchymal explants, CQ concentration clinically achievable in the lung (100µM) inhibited the lipopolysaccharide-induced release of TNF-ɑ (by 76%), IL-6 (by 68%), CCL2 (by 72%), and CCL3 (by 67%). In addition to antiviral activity, CQ may also mitigate the cytokine storm associated with severe pneumonia caused by coronaviruses.
Grassin-Delyle et al., 5/8/2020, peer-reviewed, 8 authors.
Ex Vivo studies are an important part of preclinical research, however results may be very different in vivo.